| Literature DB >> 34448108 |
Jose Carlos Campos-Sánchez1, Javier Mayor-Lafuente1, Francisco A Guardiola1, María Ángeles Esteban2.
Abstract
Inflammation is one of the main causes of loss of homeostasis at both the systemic and molecular levels. The aim of this study was to investigate in silico the conservation of inflammation-related proteins in the gilthead seabream (Sparus aurata L.). Open reading frames of the selected genes were used as input in the STRING database for protein-protein interaction network analysis, comparing them with other teleost protein sequences. Proteins of the large yellow croaker (Larimichthys crocea L.) presented the highest percentages of identity with the gilthead seabream protein sequence. The gene expression profile of these proteins was then studied in gilthead seabream specimens subcutaneously injected with carrageenin (1%) or phosphate-buffered saline (control) by analyzing skin samples from the injected zone 12 and 24 h after injection. Gene expression analysis indicated that the mechanisms necessary to terminate the inflammatory response to carrageenin and recover skin homeostasis were activated between 12 and 24 h after injection (at the tested dose). The gene analysis performed in this study could contribute to the identification of the main mechanisms of acute inflammatory response and validate the use of carrageenin as an inflammation model to elucidate these mechanisms in fish.Entities:
Keywords: Aquaculture; Carrageenin; Gene expression; In silico analysis; Skin inflammation; Teleosts
Mesh:
Substances:
Year: 2021 PMID: 34448108 PMCID: PMC8478728 DOI: 10.1007/s10695-021-00999-6
Source DB: PubMed Journal: Fish Physiol Biochem ISSN: 0920-1742 Impact factor: 2.794
Primers used for real-time qPCR
| Gene name | Gene abbreviation | GenBank number | Primer sequences (5′ → 3′) | Primer efficiencies |
|---|---|---|---|---|
| NADPH oxidase, subunit Phox40 | AM749961 | F: GCGGAGTTGAACCTGAAGAG R: TCACCTTCTGTGTCGCTGTC | 106.37% | |
| Colony-stimulating factor receptor 1 | AM050293 | F: ACGTCTGGTCCTATGGCATC R: AGTCTGGTTGGGACATCTGG | 91.53% | |
| NADPH oxidase, subunit Phox22 | FM148169 | F: CATCAAGAATCCCCCTCAGA R: TGACAGAGATGGGGTTGTCA | 96.26% | |
| Major histocompatibility complex class IIa | DQ019401 | F: CTGGACCAAGAACGGAAAGA R: CATCCCAGATCCTGGTCAGT | 114.95% | |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 | B012900 | F: ATCACAGCGCAGAGATCGAG R: TGCGGGATGTAGGTGAACTG | 94.67% | |
| Signal transducer and activator of transcription 3 | B015325 | ACATCCTTGGCACCAACACA ACCATTGCCACACCTCTGTT | 97.10% | |
| TNF receptor-associated factor 6 | B010645 | ACCTGTGTCGTGCCAAGATT TCACAGTACTGGCACGTCAC | 96.84% | |
| Toll-like receptor 2 | B008611 | F: TCCATGCTTTCGTCCAGGAC R: ACTGTGTTGAGCAAGGCCTC | 95.94% | |
| Tumor necrosis factor alpha | AJ413189 | F: CTGTGGAGGGAAGAATCGAG R: TCCACTCCACCTGGTCTTTC | 112.93% | |
| Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma | B006470 | GAAGGAGGAGGTGGAGCAAC CTCTCTCGCTTCTCGCTCTG | 104.24% | |
| MYD88 innate immune signal transduction adaptor | B013233 | GCCTTCATCTGCTACTGCCA TCTGTCGAACACGCACAGTT | 100.69% | |
| v-rel avian reticuloendotheliosis viral oncogene homolog A | B030837 | F: GAACCCCACCCTCATGAGTG R: GTTCTGGGCAGCAGTAGAGG | 109.93% | |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | B005908 | F: CCGACAGACGTTCACAGACA R: TCTTCAGCTGGACGAACACC | 98.33% | |
| v-rel avian reticuloendotheliosis viral oncogene homolog | B018958 | F: AAGCAAGAGCCCCAGATCAC R: TAGGGCGAGGAAGCAAGTTG | 104.50% | |
| v-rel avian reticuloendotheliosis viral oncogene homolog B | B012502 | F: ACAGAGGAGGTGGAGGTCAG R: TATGGATCTGGGTTGTGCGG | 106.97% | |
| Tumor necrosis factor receptor superfamily, member 1a | B006439 | F: TCTTGCGTCTGCTCTCAGTG R: CCTCAGCATCTGGTACTGCC | 96.18% | |
| Toll-like receptor 5 | B001824 | F: CAACTTGAGCTCCAACGCAC R: GGCTGGAGATAGGTCAAGGC | 95.54% | |
| Toll-like receptor 7 | B004477 | F: CCAACAATGGGAGCATGGTG R: ATGGTGAGAGTCAGGTTGGTG | 104.10% | |
| Interleukin-1 receptor-associated kinase 1 | B011814 | TGGTGCTGCTGGAGATTCTG AACCGTTCGGACTTTCCTCC | 96.39% | |
| Toll-like receptor 8 | B024796 | F: CCAGAGCAATTCCAGGGCTA R: TGTCCAGCCCTTTGAACTCTG | 90.43% | |
| Interleukin-1 | AJ277166 | F: GCGAGCAGAGGCACTTAGTC R: GGTAGGTCGCCATGTTCAGT | 103.50% | |
| Toll-like receptor 13 | B003345 | F: CCTCCCTGCCTTGACGTATC R: TGTCTGGTTGTTGCTCTGCA | 112.59% | |
| Tumor necrosis factor receptor superfamily, member 1b | B026296 | F: TACCGCAGCTCTTCACGATC R: ACTGTGTGGGGATGCTGATC | 98.91% | |
| Interleukin-7 | JX976618 | F: GATCTGGAAAACACCGGAGA R: TGGACGTGCGTTCTGGTAGC | 98.85% | |
| Interleukin-18 | JX976626 | F: TTGAGGGGTTGTCCTGTTTC R: AGTTTTTACCCCAGCCCTGT | 90.32% | |
| Interleukin-6 | AM749958 | F: AGGCAGGAGTTTGAAGCTGA R: ATGCTGAAGTTGGTGGAAGG | 96.80% | |
| Interleukin-8 | AM765841 | F: GCCACTCTGAAGAGGACAGG R: TTTGGTTGTCTTTGGTCGAA | 105.99% | |
| Toll-like receptor 9 | B030920 | F: GATCACACCGTTCACTGTCTC R: GGAGGAGAGGGACTGGATTC | 98.09% | |
| Acetylcholinesterase | B017377 | F: CGGAGTGGATGGGTGTGATC R: GTCGGCTCAGTTTCTCCTCC | 90.82% | |
| Cathepsin D | B000122 | F: TCGCTGCCTGTTGTCTCTTT R: GCCCGACAGACAGATTGACA | 112.76% | |
| Cholinergic receptor, nicotinic, alpha 7 | B000251 | F: AATGCCAGCCACAGAGATCC R: TGATTTGGGTCCAGCTCTGC | 109.85% | |
| NLR family, CARD domain containing 3 | B000011 | F: CTGCCAGTGGTCAAAGCCTC R: AGGACTGGGAGCTGAGAACT | 98.23% | |
| NLR family member X1 | B002577 | F: AGGTGTACCAAAGAGCCACG R: CTGAGGATGGGATGCCAGTC | 105.71% | |
| Cathepsin S | B007924 | F: AACCTGGTGGACTGTTCGTC R: GCGTCAGAGTCGATACCCTG | 106.63% | |
| Cathepsin L | B019572 | F: ATGATGAGCCAGACTGCAGC R: AGACCCCAGCTGTTCTTGAC | 113.90% | |
| Butyrylcholinesterase | B013682 | F: CAGGTACTCCCAACACGGTG R: ATCTCGTAGCCGTGCATGAC | 107.75% | |
| Interleukin-10 | FG261948 | F: CTCACATGCAGTCCATCCAG R: TGTGATGTCAAACGGTTGCT | 98.06% | |
| Transforming growth factor 1 beta | AF424703 | F: GCATGTGGCAGAGATGAAGA R: TTCAGCATGATACGGCAGAG | 94.54% | |
| NLR family, CARD domain containing 5 (isoform 1) | B003870 | F: AGCAGCTAGTTTGGCCTCTG R: GGCGATGTGTTTGATCCCTG | 105.93% | |
| NLR family, CARD domain containing 5 (isoform 2) | B003870 | F: CAAGAGTGATGCCCCTGTGT R: GACTGTGAGGCTCTGAGCAG | 81.50% | |
| Ribosomal protein S18 | AM490061 | F: CGAAAGCATTTGCCAAGAAT R: AGTTGGCACCGTTTATGGTC | 139.43% | |
| Elongation factor-1 alfa | AF184170 | F: TGTCATCAAGGCTGTTGAGC R: GCACACTTCTTGTTGCTGGA | 110.84% | |
| Actin beta | X89920 | F: GGCACCACACCTTCTACAAATG R: GTGGTGGTGAAGCTGTAGCC | 103.07% |
Similar organisms that match the gilthead seabream (Sparus aurata) protein sequence ordered according to the number of proteins matched
| Organism | Number of proteins matched | Range of proteins identity matched |
|---|---|---|
| 36 | 93.8–40.2% | |
| 35 | 97.8–44.6% | |
| 35 | 96.0–49.3% | |
| 35 | 91.7–41.8% | |
| 35 | 95.9–37.6% | |
| 35 | 90.4–32.4% | |
| 35 | 91.2–35.6% | |
| 35 | 94.3–35.9% | |
| 34 | 95.5–32.2% | |
| 34 | 98.7–45.0% | |
| 34 | 94.2–39.5% | |
| 34 | 95.9–46.4% | |
| 33 | 86.6–40.3% | |
| 33 | 94.6–36.8% | |
| 32 | 93.5–36.1% | |
| 31 | 93.1–36.3% | |
| 31 | 94.6–34.6% | |
| 30 | 91.5–32.8% | |
| 28 | 95.2–38.5% |
Protein prediction analysis between gilthead seabream (Sparus aurata) and Larimichthys crocea ordered from the highest to the lowest identity
| Matching proteins in | Annotation | Identity | |||
|---|---|---|---|---|---|
| Cell marker | PHOX40 | NCF4 | Neutrophil cytosol factor 4 | 91.5% | 8.4e-133 |
| CSF1R | CSF1R1 | Macrophage colony-stimulating factor 1 receptor isoform X1 | 91.0% | 0.0 | |
| PHOX22 | XP_010739797.1 | Cytochrome b-245 light chain | 89.7% | 8e-85 | |
| MHC-II | XP_010754186.1 | The sequence of the model RefSeq protein was modified relative to its source genomic sequence to represent the inferred CDS: added 285 bases not found in genome assembly | 67.1% | 6.8e-84 | |
| Pro-inflammatory proteins | NF-κB2 | NFKB2 | Nuclear factor NF-kappa-B p100 subunit isoform X1 | 97.8% | 2.4e-205 |
| STAT3 | STAT3 | Signal transducer and activator of transcription 3 isoform X1 | 96.7% | 0.0 | |
| TRAF6 | TRAF6 | TNF receptor-associated factor 6; the sequence of the model RefSeq protein was modified relative to its source genomic sequence to represent the inferred CDS: deleted 1 base in 1 codon | 89.1% | 6.5e-311 | |
| TLR2 | EH28_06854 | Toll-like receptor 2 type-2 | 85.0% | 1.7e-108 | |
| TNF-α | EH28_05037 | Tumor necrosis factor-like | 84.7% | 3.5e-28 | |
| IκBKG | IKBKG | Inhibitor of nuclear factor kappa B kinase subunit gamma; NF-kappa-B essential modulator isoform X1 | 83.2% | 2.2e-245 | |
| MYD88 | MYD88 | Myeloid differentiation primary response protein MyD88 | 83.0% | 1.4e-139 | |
| RelA | RELA | Transcription factor p65; the sequence of the model RefSeq protein was modified relative to its source genomic sequence to represent the inferred CDS: deleted 1 base in 1 codon | 82.3% | 3.7e-283 | |
| NF-κB1 | NFKB1 | The sequence of the model RefSeq protein was modified relative to its source genomic sequence to represent the inferred CDS: deleted 4 bases in 3 codons | 82.0% | 3.8e-36 | |
| C-Rel | EH28_06409 | Proto-oncogene c-Rel | 81.3% | 3e-304 | |
| RelB | RELB | Transcription factor RelB | 81.1% | 1.5e-265 | |
| TNFRSF1A | EH28_04263 | Tumor necrosis factor receptor superfamily member 1A; derived by automated computational analysis using gene prediction method: Gnomon. Supporting evidence includes similarity to: 1 Protein, and 100% coverage of the annotated genomic feature by RNAseq alignments, including 2 samples with support for all annotated introns | 72.9% | 2.5e-85 | |
| TLR5 | XP_010754180.1 | Toll-like receptor 5 | 70.2% | 4.6e-63 | |
| TLR7 | TLR7 | Toll-like receptor 7 | 69.4% | 3.8e-24 | |
| IRAK1 | EH28_12873 | Interleukin-1 receptor-associated kinase 1-like | 66.1% | 2.8e-176 | |
| TLR8 | XP_010741343.1 | Toll-like receptor 8 | 64.6% | 5.5e-198 | |
| IL-1β | IL-1β | Interleukin-1 beta-like | 62.1% | 9e-79 | |
| TLR13 | EH28_03283 | Toll-like receptor 13; derived by automated computational analysis using gene prediction method: Gnomon. Supporting evidence includes similarity to: 48 proteins | 49.7% | 3.2e-82 | |
| TNFRSF1B | TNFRSF1B | Tumor necrosis factor receptor superfamily member 1B; derived by automated computational analysis using gene prediction method: Gnomon. Supporting evidence includes similarity to: 4 proteins, and 100% coverage of the annotated genomic feature by RNAseq alignments, including 3 samples with support for all annotated introns | 44.6% | 1.2e-95 | |
| IL-7 | [STRING found no matching protein in its database] | - | - | - | |
| IL-18 | [STRING found no matching protein in its database] | - | - | - | |
| IL-6 | - | - | - | - | |
| IL-8 | - | - | - | - | |
| TLR9 | - | - | - | - | |
| Anti-inflammatory proteins | AChE | ACHE | Acetylcholinesterase | 91.3% | 0.0 |
| CTSD | XP_010735640.1 | Cathepsin D-like | 90.4% | 2e-213 | |
| nAChRα7 | EH28_10415 | Neuronal acetylcholine receptor subunit alpha-7; derived by automated computational analysis using gene prediction method: Gnomon. Supporting evidence includes similarity to: 11 proteins | 89.1% | 6.5e-24 | |
| NLRC3 | EH28_01217 | Protein NLRC3-like | 88.2% | 4e-57 | |
| NLRX1 | NLRX1 | NLR family member X1 | 86.9% | 0.0 | |
| CTSS | CTSS | Cathepsin S | 85.7% | 3.5e-34 | |
| CTSL | EH28_09355 | Cathepsin L1-like | 85.4% | 1.8e-172 | |
| BChE | XP_010750341.1 | Acetylcholinesterase-like | 76.8% | 1.2e-267 | |
| IL-10 | IL10 | Interleukin-10 | 76.4% | 3.1e-34 | |
| TGF-β | XP_010748216.1 | Transforming growth factor beta-1-like | 72.5% | 8.8e-155 | |
| NLRC5 Iso 1 | NLRC5 | NLR family CARD domain containing 5 | 70.3% | 0.0 | |
| NLRC5 Iso 2 | NLRC5 | NLR family CARD domain containing 5; protein NLRC5-like | 59.9% | 4e-170 |
Functional protein association networks of Larimichthys crocea obtained from the gilthead seabream (Sparus aurata) protein sequence
| Number of nodes | Number of edges | Average node degree | Avg. local clustering coefficient | Expected number of edges | PPI enrichment |
|---|---|---|---|---|---|
| 34 | 125 | 7.35 | 0.688 | 6 | < 1.0e-16 |
Fig.1Representation of the node network (selected proteins) of Larimichthys crocea generated from the Sparus aurata protein sequence using the STRING database (see protein annotation in Table 3). The different edge colors indicate the type of evidence for each interaction: cyan = curated STRING database; purple = experimentally determined; green = gene neighborhood; blue = gene co-occurrence; light green = text mining; black = co-expression; lavender = protein homology (the types of evidence are not mutually exclusive)
Fig. 2Relative expression of A csfr1, B phox22, C phox40, and D mhciia in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). The asterisks denote significant differences between the carrageenin and control groups (two-way ANOVA; p < 0.05)
Fig. 3Relative expression of A c-rel, B rela, C relb, D nf-κb1, and E nf-κb2 in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). The asterisks denote significant differences between the carrageenin and control groups (two-way ANOVA; p < 0.05)
Fig. 4Relative expression of A il-1β, B tnf-α, C il-6, D il-7, E il-8, and F il-18 in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). No significant differences were obtained neither between the carrageenin and control groups nor between the sampling time points (two-way ANOVA p < 0.05)
Fig. 5Relative expression of A tlr2, B tlr5, C tlr7, D tlr8, E tlr9, F tlr13, G tnfrsf1a, and H tnfrsf1b in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). No significant differences were obtained neither between the carrageenin and control groups nor between the sampling time points (two-way ANOVA; p < 0.05)
Fig. 6Relative expression of A myd88, B irak1, C traf6, D stat3, and E ikbkg (NEMO) in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). No significant differences were obtained neither between the carrageenin and control groups nor between the sampling time points (two-way ANOVA; p < 0.05)
Fig. 7Relative expression of A il10, B tgf-b, C ctsd, D ctsl, and E ctss in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). No significant differences were obtained neither between the carrageenin and control groups nor between the sampling time points (two-way ANOVA; p < 0.05)
Fig. 8Relative expression of A nlrc3, B isoform 1 of nlrc5, C isoform 2 of nlrc5, D nlrx1, E ache, F bche, and G chrna7 in gilthead seabream injected with PBS (control, white bars) and carrageenin (1%, black bars) analyzed in skin samples collected 12 and 24 h after injection. The bars represent the mean ± standard error of the mean (n = 4). No significant differences were obtained neither between the carrageenin and control groups nor between the sampling time points (two-way ANOVA; p < 0.05)
Fig. 9Proposed schematic inflammatory model of carrageenin–transduction pathway for acidophilic granulocytes in the skin of gilthead seabream. The + and − symbols represent induction and repression interactions, respectively